Clinical Trials Directory

Trials / Sponsors / Cullinan Therapeutics Inc.

Cullinan Therapeutics Inc.

Industry · 10 registered clinical trials — 5 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Dis
Sjögren, Sjogren Disease, Sjogren's Syndrome
Phase 12025-10-01
RecruitingA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Ar
Rheumatoid Arthritis (RA
Phase 12025-05-19
RecruitingA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupu
SLE, SLE (Systemic Lupus)
Phase 12025-01-21
Active Not RecruitingA Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Phase 12024-09-03
RecruitingCLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12023-12-12
Active Not RecruitingA Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
NHL, NHL, Relapsed, Adult
Phase 12023-05-31
RecruitingCLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 12021-11-18
Active Not RecruitingA Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumor, NSCLC
Phase 12021-10-29
Active Not RecruitingA Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Phase 1 / Phase 22019-10-31
TerminatedPhase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1 / Phase 22019-04-04